# A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

> **NCT06435429** · PHASE3 · RECRUITING · sponsor: **Jazz Pharmaceuticals** · enrollment: 550 (estimated)

## Conditions studied

- Metastatic HER2-positive Breast Cancer

## Interventions

- **DRUG:** Zanidatamab
- **DRUG:** Trastuzumab
- **DRUG:** Eribulin
- **DRUG:** Vinorelbine
- **DRUG:** Gemcitabine
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06435429
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-13
- **Primary completion:** 2028-04-28
- **Final completion:** 2030-10-18
- **Target enrollment:** 550 (ESTIMATED)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06435429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06435429, "A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06435429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*